HomeCompareJXMNF vs MRK

JXMNF vs MRK: Dividend Comparison 2026

JXMNF yields 27586.21% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JXMNF wins by $1.2819158619706528e+21M in total portfolio value
10 years
JXMNF
JXMNF
● Live price
27586.21%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.2819158619706528e+21M
Annual income
$1,272,839,341,780,023,800,000,000,000.00
Full JXMNF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — JXMNF vs MRK

📍 JXMNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJXMNFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JXMNF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JXMNF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JXMNF
Annual income on $10K today (after 15% tax)
$2,344,827.59/yr
After 10yr DRIP, annual income (after tax)
$1,081,913,440,513,020,200,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, JXMNF beats the other by $1,081,913,440,513,020,200,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JXMNF + MRK for your $10,000?

JXMNF: 50%MRK: 50%
100% MRK50/50100% JXMNF
Portfolio after 10yr
$640957930985326379008.00M
Annual income
$636,419,670,890,011,900,000,000,000.00/yr
Blended yield
99.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

JXMNF
No analyst data
Altman Z
-2.0
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JXMNF buys
0
MRK buys
0
No recent congressional trades found for JXMNF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJXMNFMRK
Forward yield27586.21%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$1.2819158619706528e+21M$56.8K
Annual income after 10y$1,272,839,341,780,023,800,000,000,000.00$9,798.13
Total dividends collected$1.281318375662854e+21M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JXMNF vs MRK ($10,000, DRIP)

YearJXMNF PortfolioJXMNF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,769,321$2,758,620.69$11,206$366.19+$2.76MJXMNF
2$716,935,636$713,972,462.69$12,650$502.35+$716.92MJXMNF
3$173,511,769,409$172,744,648,278.75$14,407$694.19+$173511.76MJXMNF
4$39,258,013,175,119$39,072,355,581,851.33$16,585$967.82+$39258013.16MJXMNF
5$8,304,006,152,937,922$8,262,000,078,840,545.00$19,342$1,363.89+$8304006152.92MJXMNF
6$1,642,165,733,864,218,000$1,633,280,447,280,574,700.00$22,913$1,947.19+$1642165733864.20MJXMNF
7$303,617,632,363,747,300,000$301,860,515,028,512,540,000.00$27,662$2,823.89+$303617632363747.25MJXMNF
8$52,484,264,573,149,000,000,000$52,159,393,706,519,790,000,000.00$34,159$4,173.35+$52484264573149000.00MJXMNF
9$8,482,729,150,120,307,000,000,000$8,426,570,987,027,038,000,000,000.00$43,337$6,308.80+$8482729150120306688.00MJXMNF
10$1,281,915,861,970,652,700,000,000,000$1,272,839,341,780,023,800,000,000,000.00$56,776$9,798.13+$1.2819158619706528e+21MJXMNF

JXMNF vs MRK: Complete Analysis 2026

JXMNFStock

Jaxon Mining Inc. operates as a mineral exploration and development company in Canada. The company explores for silver, gold, zinc, copper, and lead deposits. It holds interests in the Red Springs Project, which consists of 19 mineral claims that covers an area of 291.88 km2 located in British Columbia; the Netalzul Mountain project that comprises of 23 claims covering an area of 130.02 km2 located in northwest British Columbia; the Max project, which consists of 6 mineral claims covering an area of 90 km2; and the Blunt Mountain property that consists of 12 mineral claims covering an area of 72 km2 located in British Columbia. The company was formerly known as Jaxon Minerals Inc. and changed its name to Jaxon Mining Inc. in August 2017. Jaxon Mining Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full JXMNF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this JXMNF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JXMNF vs SCHDJXMNF vs JEPIJXMNF vs OJXMNF vs KOJXMNF vs MAINJXMNF vs JNJJXMNF vs ABBVJXMNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.